The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
908
October 29, 1993
View Complete Issue         Table of Contents 2019 
Radioactive Strontium-89 for Painful Bone Metastases
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Radioactive Strontium-89 for Painful Bone Metastases
October 29, 1993 (Issue: 908)
Strontium-89 chloride was recently approved for marketing by the US Food and Drug Administration. It is offered for relief of pain caused by metastatic bone lesions
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Radioactive Strontium-89 for Painful Bone Metastases
Article code: 908b
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.